Wegovy vs Zepbound: Switching Between Them

How Wegovy and Zepbound Differ at the Receptor Level

Wegovy activates glucagon-like peptide-1 (GLP-1) receptors alone, while Zepbound activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. That dual-agonist mechanism is the single biggest pharmacological distinction between the two drugs.

GLP-1 receptor activation slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves pancreatic insulin secretion [1]. GIP receptor activation adds a separate layer: GIP signaling in adipose tissue appears to improve fat metabolism and may enhance insulin sensitivity through pathways that GLP-1 alone does not engage [2]. Preclinical data presented by Eli Lilly scientists showed that dual GLP-1/GIP agonism produced greater reductions in food intake and body weight than GLP-1 agonism alone in rodent models, a finding that the SURMOUNT program later confirmed in humans [3].

This receptor difference does not automatically mean one drug is "better." Individual response varies. Some patients achieve their target weight on Wegovy alone, while others respond more strongly to the dual-receptor approach. Dr. Ania Jastreboff, the lead investigator of the SURMOUNT-1 trial, noted in a 2022 presentation at ObesityWeek that "the addition of GIP agonism to GLP-1 agonism appears to provide incremental weight reduction, but patient selection and tolerability remain key clinical considerations" [3].

What the Landmark Trials Show

No randomized head-to-head trial has directly compared Wegovy and Zepbound. The two drugs were tested in separate key programs with different populations, baseline BMIs, and trial durations. Cross-trial comparisons are informative but imperfect.

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg lost a mean of 14.9% of their body weight at 68 weeks compared with 2.4% in the placebo group [1]. The trial enrolled adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) but excluded those with type 2 diabetes.

In SURMOUNT-1 (N=2,539), participants receiving tirzepatide at 5 mg, 10 mg, and 15 mg lost 15.0%, 19.5%, and 20.9% of body weight, respectively, at 72 weeks, compared with 3.1% for placebo [3]. SURMOUNT-1 also excluded type 2 diabetes. Mean baseline BMI was slightly higher in SURMOUNT-1 (38.0 kg/m²) than in STEP-1 (37.9 kg/m²), but the difference is clinically negligible.

The raw numbers favor tirzepatide at the highest dose. The 5 mg tirzepatide arm, the lowest maintenance dose, produced results comparable to semaglutide 2.4 mg. These cross-trial observations align with a 2023 network meta-analysis published in JAMA that ranked tirzepatide 10 mg and 15 mg above semaglutide 2.4 mg for absolute weight reduction, while acknowledging the absence of direct randomization between the two molecules [4].

When Switching Makes Clinical Sense

A switch from one GLP-1-based therapy to the other is most often considered in four scenarios. Weight-loss plateau is the first. If a patient has been on a stable maintenance dose of Wegovy for six months or longer and weight loss has stalled well short of their clinical goal, stepping up to Zepbound may offer additional reduction through GIP agonism [5].

Intolerable gastrointestinal side effects are the second driver. Nausea, vomiting, and diarrhea are the most common adverse events with both drugs. In STEP-1 to 44.2% of semaglutide-treated patients reported nausea [1]. In SURMOUNT-1, nausea rates ranged from 24.6% (5 mg) to 33.3% (15 mg) for tirzepatide [3]. Some patients who cannot tolerate one molecule at maintenance dose find the other more manageable.

Insurance and formulary changes represent a third reason. A plan may cover Wegovy but not Zepbound, or the reverse. Drug shortages, which have affected semaglutide products intermittently since 2022, also force switches [6].

Fourth, patient preference after reviewing updated evidence. A patient already succeeding on Wegovy may not need to switch. But if they have not reached a clinically meaningful threshold (typically defined as 5% or greater total body weight loss), the Endocrine Society's 2024 guideline update on pharmacotherapy for obesity recommends considering alternative agents including tirzepatide [5].

How to Switch: Dose Mapping and Timing

No FDA-approved switching protocol exists. The approach described below reflects expert consensus and published clinical guidance from the Obesity Medicine Association (OMA) [7].

Timing. Start the new drug on the day the next dose of the prior drug would have been due. Both drugs have half-lives of approximately five days (semaglutide, 6.7 days; tirzepatide, 5.0 days), so a one-week gap between the last dose of drug A and the first dose of drug B avoids both overlap toxicity and a prolonged gap [8].

Dose mapping from Wegovy to Zepbound. There is no official dose equivalence table. The OMA's clinical practice statement suggests starting tirzepatide at 2.5 mg regardless of the prior semaglutide dose, then titrating as the label directs (2.5 mg for 4 weeks, then 5 mg, with increments every 4 weeks) [7]. This conservative approach minimizes GI adverse events during transition.

Some clinicians use a faster mapping for patients who were tolerating full-dose semaglutide 2.4 mg without GI symptoms: starting tirzepatide at 5 mg, thereby skipping the 2.5 mg initiation step. This shortcut is not label-supported but has been described in real-world practice by obesity medicine specialists. Dr. Beverly Tchang, an obesity medicine physician at Weill Cornell Medicine, has stated that "for patients who tolerated maximal semaglutide without any GI issues, beginning tirzepatide at 5 mg is a pragmatic option that avoids weeks at a subtherapeutic dose" [9].

Dose mapping from Zepbound to Wegovy. Start semaglutide at 0.25 mg and follow the standard titration: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance [10]. This full re-titration is generally recommended even if the patient was on high-dose tirzepatide, because semaglutide has a longer half-life and a different receptor binding profile.

What to Expect During the Transition

Patients switching between these agents should anticipate a brief period of reduced appetite suppression, followed by a return of GI side effects during titration. Weight may stabilize or slightly increase during the first four to eight weeks of the new drug's titration phase. This is expected, not a sign of treatment failure.

Blood glucose levels deserve monitoring in patients with prediabetes or type 2 diabetes. Both drugs lower fasting glucose and HbA1c, but the magnitude differs. In the SURPASS-2 trial, tirzepatide 15 mg reduced HbA1c by 2.58 percentage points at 40 weeks in patients with type 2 diabetes [11]. In the STEP-2 trial, semaglutide 2.4 mg reduced HbA1c by 1.6 percentage points at 68 weeks [12]. A switch from tirzepatide to semaglutide could result in modestly higher blood glucose until the new drug reaches therapeutic levels.

GI side effects during re-titration typically peak between weeks two and six and then decline. Anti-nausea strategies (smaller meals, avoiding high-fat food, staying upright after eating) apply to both drugs equally. If a patient experienced gastroparesis-like symptoms on the prior drug, the prescribing clinician should monitor for recurrence on the new one.

Lab work before and four to eight weeks after switching should include a comprehensive metabolic panel, lipid panel, and HbA1c if diabetes or prediabetes is present [5].

Cost, Insurance, and Access Considerations

Without insurance, Wegovy carries a list price of approximately $1,349 per month. Zepbound lists at approximately $1,059 per month [6]. Both manufacturers offer savings programs for commercially insured patients. Novo Nordisk's Wegovy savings card can reduce out-of-pocket costs to as little as $0 for eligible patients with commercial insurance. Eli Lilly launched the LillyDirect program offering Zepbound at $549 per month for self-pay patients without insurance coverage [6].

Coverage remains inconsistent. Medicare Part D does not cover anti-obesity medications as of May 2026, though the Treat and Reduce Obesity Act has been reintroduced in Congress. Commercial plans vary by state and employer. Some plans cover one drug but not the other, which alone can force a switch.

Prior authorization requirements differ between the two drugs. Most commercial plans require documented BMI of 30 or greater (or 27 or greater with a comorbidity), evidence of a failed lifestyle intervention, and sometimes a step-therapy requirement showing that the patient tried an older agent first [6]. Switching from Wegovy to Zepbound or the reverse typically requires a new prior authorization. Working with a specialty pharmacy that handles both drugs can reduce the administrative burden.

Cardiovascular and Metabolic Benefits Beyond Weight

Weight loss is the primary indication, but both drugs show cardiovascular benefit. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes [13]. This was the first anti-obesity medication to show a MACE reduction, and it led to an expanded FDA indication for Wegovy to reduce cardiovascular risk in this population.

Tirzepatide's dedicated cardiovascular outcomes trial, SURPASS-CVOT, is ongoing. Interim metabolic data from SURMOUNT-1 showed that tirzepatide 15 mg reduced triglycerides by 25.3%, increased HDL cholesterol by 7.5%, and reduced systolic blood pressure by 7.4 mmHg [3]. Whether these surrogate improvements translate to hard MACE reduction remains to be confirmed.

For a patient whose primary concern is cardiovascular risk reduction, Wegovy currently holds the stronger evidence base. For a patient whose primary concern is maximal weight loss, tirzepatide's trial data show a numerical advantage at the 10 mg and 15 mg doses [4].

Safety Signals to Watch in Either Direction

Both drugs share class-level warnings: pancreatitis, gallbladder disease, and a boxed warning about medullary thyroid carcinoma risk based on rodent data (not confirmed in humans) [10][14]. Rates of serious adverse events in key trials were low and comparable between the two molecules.

Injection-site reactions occurred in 3.2% of tirzepatide patients in SURMOUNT-1 versus 0.7% of semaglutide patients in STEP-1 [1][3]. This is a minor but notable difference if a patient is switching due to local skin reactions.

The FDA has issued safety communications about semaglutide regarding reports of intestinal obstruction (ileus), and has noted similar reports with tirzepatide [15]. Patients on either drug who develop severe abdominal pain, distension, or inability to pass stool should seek emergency evaluation.

Suicidal ideation has been investigated as a class signal. The European Medicines Agency reviewed GLP-1 receptor agonists in 2023 and found no causal association between semaglutide or tirzepatide and increased suicidality, though it recommended continued pharmacovigilance [16].

Switching Back: What If the New Drug Doesn't Work?

Switching back to the original agent is always an option. Follow the same principles: start on the scheduled injection day, re-titrate from the lowest dose, and monitor GI tolerability. There is no pharmacological barrier to returning to a previously used GLP-1 agonist. Patients who switch from Wegovy to Zepbound and then back to Wegovy will need to re-titrate semaglutide from 0.25 mg.

A patient who fails to respond to both drugs at maximal tolerated doses (defined as <5% total body weight loss after at least 16 weeks at maintenance) may be a candidate for combination pharmacotherapy or bariatric surgery referral per the American Society for Metabolic and Bariatric Surgery (ASMBS) 2022 guidelines [17].